Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents

OncoTargets and Therapy

Volumn 4, Issue , 2011, Pages 137-148

  Khan, Mohammad K ^a   Khan, Niloufer ^b   Almasan, Alex ^a,b   Macklis, Roger ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; Hypofractionation radiotherapy; Melanoma cell cycle; Radiosurgery; Systemic agents; Targeted biologic agents

Indexed keywords

ALPHA2B INTERFERON; IPILIMUMAB;

BRAIN METASTASIS; BRAIN RADIATION; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CHEMORADIOTHERAPY; HEAD AND NECK CANCER; HUMAN; MALIGNANT TRANSFORMATION; MELANOMA; MULTIMODALITY CANCER THERAPY; NONHUMAN; RADIATION INJURY; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; RADIOSURGERY; REVIEW; TREATMENT OUTCOME; UVEA MELANOMA;

EID: 84872679072     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S20257     Document Type: Review

References (89)

1. Algazi AP, Soon CW, Daud AI. Treatment of cutaneous melanoma: Current approaches and future prospects. Cancer Manag Res. 2010; 2:197-211.
2. Mouawad R, Sebert M, Michels J, Bloch J, Spano JP, Khayat D. T{stroke}reatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol. 2010;74:27-39.
3. Jilaveanu LB, Aziz SA, Kluger HM. Chemotherapy and biologic therapies for melanoma: Do they work? Clin Dermatol. 2009;27:614-625.
4. MacKee GM, Cipollaro AC, Montgomery H. X-rays and Radium in the Treatment of Diseases of the Skin. 4th ed. Philadelphia, PA: Lea and Febiger; 1946.
5. Million RR, Cassisi NJ. Management of Head and Neck Cancer: A Multidisciplinary Approach. Philadelphia, PA: Lippincott; 1984.
6. Jenrette JM. Malignant melanoma: the role of radiation therapy revisited. Semin Oncol. 1996;23:759-762.
7. Stevens G, McKay MJ. Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma. Lancet Oncol. 2006; 7:575-583.
8. Overgaard J, Overgaard M, Hansen PV, von der Maase H. Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol. 1986;5:183-192.
9. Rofstad EK. Radiation biology of malignant melanoma. Acta Radiol Oncol. 1986;25:1-10.
10. Korcum AF, Sanlioglu S, Aksu G, Tuncel N, Erin N. Radiotherapyinduced decreases in substance P levels may potentiate melanoma growth. Mol Med Report. 2009;2:319-326.
11. Homer MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review,1975-2006. Bethseda, MD: National Cancer Institute; 2009. Available from: http://seer.cancer.gov/csr/1975_2006/. Accessed April 3, 2010.
12. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin J. 2009;59:225-249.
13. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27:6199-6206.
14. Rigel DS, Carucci JA. Malignant melanoma: Prevention, early detection, and treatment in the 21st century. CA Cancer J Clin. 2000; 50:215-236.
15. Network NCC. NCCN Clinical Practice Guidelines in Oncology: Melanoma. 2010. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed June 22, 2011.
16. Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer. 2003;97:1941-1946.
17. Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol. 2001;8:101-108.
18. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg. 1991;126:438-441.
19. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med. 1988;318:1159-1162.
20. Thomas JM, Newton-Bishop J, A'Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med. 2004;350:757-766.
21. Coley WB, Leucutia T. The treatment of metastatic tumors of the skin: pigmented moles and melanomas. AJR Am J Roentgenol. 1924;11:335-336.
22. Ellis F. Radiosensitivity of malignant melanomata. Br J Radiol. 1939;12:327-352.
23. Hellriegel W. Radiation therapy for primary and metastatic melanoma. Ann N Y Acad Sci. 1963;100:131-141.
24. Barranco SC, Romsdahl MM, Humphrey RM. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res. 1971;31:830-833.
25. Overgaard J, von der Maase H, Overgaard M. A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys. 1985;11:1837-1839.
26. Sause WT, Cooper JS, Rush S, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys. 1991;20:429-432.
27. Bentzen SM, Overgaard J, Thames HD, et al. Clinical radiobiology of malignant melanoma. Radiother Oncol. 1989;16:169-182.
28. Konefal JB, Emami B, Pilepich MV. Malignant melanoma: analysis of dose fractionation in radiation therapy. Radiology. 1987;164:607-610.
29. Ang KK, Byers RM, Peters LJ, et al. Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Preliminary results. Arch Otolaryngol Head Neck Surg. 1990;116:169-172.
30. Burmeister BH, Mark Smithers B, Burmeister E, et al. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) Study 96.06. Radiother Oncol. 2006;81:136-142.
31. Henderson MA, Burmeister B, Thompson JF, et al. Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: results of an Intergroup randomized trial (ANZMTG 01.02/TROG 02.01). J Clin Oncol. 2009;27(18 Suppl):Abstr LBA9084.
32. Skibber JM, Soong SJ, Austin L, Balch CM, Sawaya RE. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol. 1996;3:118-123.
33. Sampson JH, Carter JHJ, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88:11-20.
34. Mori Y, Kondziolka D, Flickinger JC, Kirkwood JM, Agarwala S, Lunsford LD. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys. 1998;42:581-589.
35. Selek U, Chang EL, Hassenbusch S Jr, et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys. 2004;59:1097-1106.
36. Yu C, Chen JC, Apuzzo ML, et al. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys. 2002;52:1277-1287.
37. Radbill AE, Fiveash JF, Falkenberg ET, et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer. 2004;101:825-833.
38. Scorsetti M, Facoetti A, Navarria P, et al. Hypofractionated stereotactic radiotherapy and radiosurgery for the treatment of patients with radioresistant brain metastases. Anticancer Res. 2009;29:4259-4263.
39. Stone A, Cooper J, Koenig KL, Golfinos JG, Oratz R. A comparison of survival rates for treatment of melanoma metastatic to the brain. Cancer Invest. 2004;22:492-497.
40. Herlyn M, Nathanson KL. Taking the guesswork out of uveal melanoma. N Engl J Med. 2010;363:2256-2257.
41. Van Raamsdonk JM, Meng Y, Camp D, et al. Decreased energy metabolism extends life span in Caenorhabditis elegans without reducing oxidative damage. Genetics. 2010;185:559-571.
42. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363:2191-2199.
43. Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: Initial mortality findings. COMS Report No. 18. Arch Ophthalmol. 2001;119:969-982.
44. Temam S, Mamelle G, Marandas P, et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer. 2005; 103:313-319.
45. Owens JM, Roberts DB, Myers JN. The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg. 2003;129: 864-868.
46. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24: 4340-4346.
47. Handolias D, Hamilton AL, Salemi R, et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer. 2010;102:1219-1223.
48. Moncrieff MD, Martin R, O'Brien CJ, et al. Adjuvant postoperative radiotherapy to the cervical lymph nodes in cutaneous melanoma: Is there any benefit for high-risk patients? Ann Surg Oncol. 2008; 15:3022-3027.
49. Ballo MT, Ang KK. Radiotherapy for cutaneous malignant melanoma: Rationale and indications. Oncology (Williston Park). 2004;18: 99-107.
50. Chang DT, Amdur RJ, Morris CG, Mendenhall WM. Adjuvant radiotherapy for cutaneous melanoma: Comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys. 2006; 66:1051-1055.
51. Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer. 2006;106:1431-1442.
52. Agrawal S, Kane JM 3rd, Guadagnolo BA, Kraybill WG, Ballo MT. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer. 2009;115:5836-5844.
53. Ballo MT, Ross MI, Cormier JN, et al. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys. 2006;64:106-113.
54. Uong A, Zon LI. Melanocytes in development and cancer. J Cell Physiol. 2010;222:38-41.
55. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355: 51-65.
56. Satyamoorthy K, Chehab NH, Waterman MJ, et al. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ. 2000;11:467-474.
57. Crosby ME, Almasan A. Opposing roles of E2Fs in cell proliferation and death. Cancer Biol Ther. 2004;3:1208-1211.
58. Almasan A, Yin Y, Kelly RE, et al. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2Fresponsive genes, and apoptosis. Proc Natl Acad Sci U S A. 1995;92: 5436-5440.
59. Mazumder S, DuPree EL, Almasan A. A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Curr Cancer Drug Targets. 2004;4:65-75.
60. Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular classification of melanoma. J Clin Oncol. 2007;25:1606-1620.
61. Nogueira C, Kim KH, Sung H, et al. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene. 2010;29:6222-6232.
62. Haferkamp S, Becker TM, Scurr LL, Kefford RF, Rizos H. p16INK 4a-induced senescence is disabled by melanoma-associated mutations. Aging Cell. 2008;7:733-745.
63. Johnson SM, Torrice CD, Bell JF, et al. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest. 2010;120:2528-2536.
64. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008;105:3041-3046.
65. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363: 809-819.
66. Gudkov AV, Komarova EA. Radioprotection: smart games with death. J Clin Invest. 2010;120:2270-2273.
67. Yang J, Splittgerber R, Yull FE, et al. Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J Clin Invest. 2010; 120:2563-2574.
68. Johnson GE, Ivanov VN, Hei TK. Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis. 2008;13:790-802.
69. Matsumura Y, Yamagishi N, Miyakoshi J, Imamura S, Takebe H. Increase in radiation sensitivity of human malignant melanoma cells by expression of wild-type p16 gene. Cancer Lett. 1997;115:91-96.
70. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
71. Kaminski JM, Shinohara E, Summers JB, Niermann KJ, Morimoto A, Brousal J. The controversial abscopal effect. Cancer Treat Rev. 2005;31:159-172.
72. Ascierto PA, Streicher HZ, Sznol M. Melanoma: A model for testing new agents in combination therapies. J Transl Med. 2010;8:38.
73. Schild SE, Behl D, Markovic SN, et al. Brain metastases from melanoma: Is there a role for concurrent temozolomide in addition to whole brain radiation therapy? Am J Clin Oncol. 2010;33: 633-636.
74. Gray RJ, Pockaj BA, Kirkwood JM. An update on adjuvant interferon for melanoma. Cancer Control. 2002;9:16-21.
75. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005; 23:275-306.
76. Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-alpha/ beta signalling to p53 responses in tumour suppression and antiviral defence. Nature. 2003;424:516-523.
77. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet. 2001;358:866-869.
78. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: The AIM HIGH Study - United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004;22: 53-61.
79. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7-17.
80. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18:2444-2458.
81. Nguyen NP, Sallah S, Childress C, Salehpour MR, Karlsson U. Interferon-alpha combined with radiotherapy in the treatment of unresectable melanoma. Cancer Invest. 2001;19:261-265.
82. Gyorki DE, Ainslie J, Joon ML, Henderson MA, Millward M, McArthur GA. Concurrent adjuvant radiotherapy and interferonalpha2b for resected high risk stage III melanoma - a retrospective single centre study. Melanoma Res. 2004;14:223-230.
83. Conill C, Jorcano S, Domingo-Domenech J, et al. Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients. Melanoma Res. 2007;17:304-309.
84. Hazard LJ, Sause WT, Noyes RD. Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: the potential for increased radiation toxicity. Int J Radiat Oncol Biol Phys. 2002;52:796-800.
85. Paul E, Muller I, Renner H, Bodeker RH, Cochran AJ. Treatment of locoregional metastases of malignant melanomas with radiotherapy and intralesional beta-interferon injection. Melanoma Res. 2003;13:611-617.
86. Mansfield AS, Markovic SN. Novel therapeutics for the treatment of metastatic melanoma. Future Oncol. 2009;5:543-557.
87. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008;180:3132-3139.
88. Le UM, Kaurin DG, Sloat BR, Yanasarn N, Cui Z. Localized irradiation of tumors prior to synthetic dsRNA therapy enhanced the resultant anti-tumor activity. Radiother Oncol. 2009;90:273-279.
89. Khan AJ, Wall BA, Ahlawat S, et al. Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. Clin Cancer Res. 2011;17:1807-1814.